Kentreck Laboratories Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 22-06-2024
- Paid Up Capital ₹ 1.51 Cr
as on 22-06-2024
- Company Age 35 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.24 Cr
as on 22-06-2024
- Revenue 19.36%
(FY 2023)
- Profit 1.32%
(FY 2023)
- Ebitda -61.98%
(FY 2023)
- Net Worth 1.67%
(FY 2023)
- Total Assets 8.78%
(FY 2023)
About Kentreck Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.51 Cr.
The company currently has active open charges totaling ₹16.24 Cr.
Kenil Shah, Himanshu Doshi, and Hiren Doshi serve as directors at the Company.
- CIN/LLPIN
U24231GJ1989PTC012216
- Company No.
012216
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 May 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Kentreck Laboratories Pvt Ltd offer?
Kentreck Laboratories Pvt Ltd offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Paracetamol Tablets, Calpol Paracetamol Tablets, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Antipyretic Medication.
Who are the key members and board of directors at Kentreck Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kenil Shah  | Director | 02-Apr-2011 | Current |
| Himanshu Doshi | Director | 20-Mar-1991 | Current |
| Hiren Doshi | Director | 10-May-1989 | Current |
Financial Performance of Kentreck Laboratories.
Kentreck Laboratories Pvt Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 19.36% increase. The company also saw a slight improvement in profitability, with a 1.32% increase in profit. The company's net worth moved up by a moderate rise of 1.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kentreck Laboratories?
In 2023, Kentreck Laboratories had a public holding of 40.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 18 Jan 2022 | ₹8.50 M | Open |
Sidbi Creation Date: 09 Jun 2020 | ₹5.00 M | Open |
Others Creation Date: 05 Mar 2003 | ₹5.82 Cr | Open |
How Many Employees Work at Kentreck Laboratories?
Kentreck Laboratories has a workforce of 17 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kentreck Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kentreck Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
